

Biomarkers for atopic dermatitis: a systematic review and meta-analysis

Judith L. Thijs¹, Todor Krastev¹, Stephan Weidinger², Constantinus F. Buckens³, Marjolein S. de Bruin-Weller¹, Carla A.F.M. Bruijnzeel-Koomen¹, Carsten Flohr⁴, DirkJan Hijnen¹

1. Department of Dermatology and Allergy, University Medical Center Utrecht, Utrecht, The Netherlands
2. Department of Dermatology, Venereology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Germany
3. Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
4. Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' Hospitals NHS Foundation Trust and King's College, London, United Kingdom

Current Opinion in Allergy and Clinical Immunology 2015 Oct;15(5):453-60.

Table S1. Data extraction

Longitudinal studies

Multiple measurements (mostly values before and after treatment)

- study size (number of patients)
- mean/median age of AD patients
- AD severity scoring system (SCORAD, SASSAD, EASI, LSS)
- mean length of follow-up (days)
- significant or non-significant changes in biomarker values and severity scores
- r-value (Spearman/Pearson correlation coefficient)

Cross-sectional studies

Single measurements in AD patients

- study size (number of patients)
- significant or non-significant correlation biomarker-scoring system?
- r-value (Spearman/Pearson correlation coefficient)

Outcome measurements

Correlation between: change in biomarker and change in clinical severity score

Table S2. Biomarkers

Biomarker	References	Biomarker	References
OxLDL	1	sIgA	2,3,4,5
p5-HT	6	sIgE	7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44, 45,2,3,4,5,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92, 93,94,95,96,97,98,99,100,101,102,103,104
pBDNF	105	sIgFLC	81
pB-TG	106	sIgG	2,3,4,5
pCD26	107	sIgM	2,4
pCD30	107	sIL-10	29,2,64,66,70,90,108,109
pCGRP	7,110	sIL-13	66,111
pCTACK	105,8,9	sIL-16	27,112,45,88,113
pEDN	114	sIL-18	115,64,70,76,93,116,117
pEotaxin	118	sIL-1ra	119
pE-selectin	120	sIL-2R	121,122,21,22,27,34,35,123,124,125,126,55,64,127,128
pICAM-1	120	sIL-2sRa	119
pIFN- γ	10	sIL-31	129,130,131,132,133,134
pIL-12	10	sIL-4	17,20,21,29,135,51,66,89,90,109,111,136,137
pIL-18	10,11	sIL-4R	124
pIL-1b	12,138	sIL-5	42,135,139,111,137
pIL-6	12	sIL-6	121,89,90
pIL-8	12	sIL-8	140
pMDC	118,10	sIL-9	141,142
pMMP-9	143	sINF- γ	2,137
pNGF	110	sIP-10	140
pNPY	7,110	sI-TAC	140
pPDMP	13	sLDH	10,52,75,83,93,97,102,104,130,144
pPF4	106	sLDH5	63
p-sPselectin	13	sLL-37	145
p substance-P	7,9	sMBP	146,147
pTARC	105, 8, 9, 118 ,10,14	sMCP-1	140

pTM	148	sMCP-1a	119
pVCAM-1	120	sMDC	30,149,112,150,43,140,126,45,79,151,152
pVEGF	153	sMIG	140
sApelin	15	sMIP1-a	140
sApril	154,155	sMIP1-b	140
sATX	156	sNGF	157,111,158,159,160,161
sBAFF	154	sNitrate	162
sBDNF	163,157	sNPY	111
sB-endorphin	16	sOX40L	108
sCD14	121,17,18,164,165	sPAFAH activity	11
sCD23	121,165,19,122,20,21,22	sPeriostin	104
sCD25	165	sRANTES	119,140
sCD26	166	sResistin	15
sCD30	165,21,22,23,167,168,24,25,26,27,169,28,	sSCCA	170
sCD4	119	sSEA-IgE	58,171,172
sCD5	29	ssKIT	173
sCD8	119	sSubstance-P	158,160,174
sCSF	173	sTARC	175,30,31,149,32,43, 140,176,79,80,93,97,100,102,104, 108,133,144,151,152,177,178,179,180,181,182,18 3,184, 185
sCTACK	186,175,187,30,31,149,32	sTGF-B1	119
sECP	163,121,17,122,24,26,30,33,34,188,189,35,36,190, 37,38,191,123,192,193,194,124,195,196,125,197,1 98,199,200,201,202,203,112,39,40,115,41,42,135, 204,205	sTNF-a	119,109,206
sEDN	114	sTryptase	78
sELAM-1	37,123,125	sTSLP	108,207
sEotaxin	27,150,43,139,140	sVAP-1	208
sEPX	199,200	sVCAM-1	202,44,209
sE-selectin	163,17,202,112,146, 210,44,211,212,176,126,209,45	sVE-cadherin	213
sGM-CSF	119	sVIP	16,214
sGROa	140	sVisfatin	15
sICAM-1	119,36,37,123,125,44,211,209	sVitD	95,215,216,217,218,219,220,221
sMEC	222,223		

Figure S1. Funnel plots of longitudinal studies








Figure S2. Funnel plots of cross-sectional studies



REFERENCES

1. Kaur S, Kullisaar T, Mikelsaar M, Eisen M, Rehema A, Vihalemm T, et al. Successful management of mild atopic dermatitis in adults with probiotics and emollients. *Central European Journal of Medicine*, 2008;215-20.
2. Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. *Br J Dermatol* 2000; 143:385-91.
3. Hon KL, Wang SS, Pong NH, Leung TF. Circulating immunoglobulins, leucocytes and complements in childhood-onset atopic eczema. *Indian J Pediatr* 2013; 80:128-31.
4. Kim JY, Park JS, Park JC, Kim ME, Nahm DH. Double-filtration plasmapheresis for the treatment of patients with recalcitrant atopic dermatitis. *Ther Apher Dial* 2013; 17:631-7.
5. Toyran M, Akan A, Erkocoglu M, Vezir E, Azkur D, Civelek E, et al. The relationship between low serum immunoglobulin levels and severity of atopic dermatitis in young children. *Pediatric, Allergy, Immunology, and Pulmonology* 2013; 26:152-6.
6. Soga F, Katoh N, Inoue T, Kishimoto S. Serotonin activates human monocytes and prevents apoptosis. *J Invest Dermatol* 2007; 127:1947-55.
7. Salomon J, Baran E. The role of selected neuropeptides in pathogenesis of atopic dermatitis. *Journal of the European Academy of Dermatology and Venereology : JEADV* 2008; 22.
8. Nakamura K. IgE and TARC (thymus and activation regulated chemokine) as diagnostic markers for the evaluation of severity of atopic dermatitis. *Skin Research* 2005; 4.
9. Hon KL, Lam MC, Leung TF, Wong KY, Chow CM, Fok TF, et al. Are age-specific high serum IgE levels associated with worse symptomatology in children with atopic dermatitis? *International journal of dermatology* 2007; 46.
10. Furukawa H, Takahashi M, Nakamura K, Kaneko F. Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. *Journal of dermatological science* 2004; 36.
11. Ohnishi H, Kato Z, Watanabe M, Fukutomi O, Inoue R, Teramoto T, et al. Interleukin-18 is associated with the severity of atopic dermatitis. *Allergology International* 2003; 52.
12. Kimata H, Lindley I. Detection of plasma interleukin-8 in atopic dermatitis. *Archives of Disease in Childhood*, 1994:119-22.
13. Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Platelet-derived microparticles and soluble P-selectin as platelet activation markers in patients with atopic dermatitis. *Clin Immunol* 2009; 131:495-500.

14. Yoshida Y, Seki T, Matsunaka H, Watanabe T, Shindo M, Yamada N, et al. Clinical effects of probiotic bifidobacterium breve supplementation in adult patients with atopic dermatitis. *Yonago acta medica* 2010; 53.
15. Machura E, Szczepanska M, Ziora K, Ziora D, Swietochowska E, Barc-Czarnecka M, et al. Evaluation of adipokines: apelin, visfatin, and resistin in children with atopic dermatitis. *Mediators Inflamm* 2013; 2013:760691.
16. Lee CH, Chuang HY, Shih CC, Jong SB, Chang CH, Yu HS. Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. *Br J Dermatol* 2006; 154:1100-7.
17. Furue M, Koga T, Yamashita N. Soluble E-selectin and eosinophil cationic protein are distinct serum markers that differentially represent clinical features of atopic dermatitis. *The British journal of dermatology* 1999; 140.
18. Hon KL, Ching GK, Leung TF, Chow CM, Lee KK, Ng PC. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. *J Dermatolog Treat* 2009; 20:141-5.
19. Muller KM, Rocken M, Joel D, Bonnefoy JY, Saurat JH, Hauser C. Mononuclear cell-bound CD23 is elevated in both atopic dermatitis and psoriasis. *J Dermatol Sci* 1991; 2:125-33.
20. Hatzistilianou M, Aggouridaki C, Catriu D, Athanassiadou F. IL-4 and SCD23 in children with atopic dermatitis. *European journal of pediatrics* 1996; 155.
21. Bottari V, Frezzolini A, Ruffelli M, Puddu P, Fontana L, De Pita O. Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention. *Allergy* 1999; 54.
22. Cavagni G, Caffarelli C, Facchetti F, Brugnoli D, Notarangelo LD, Tosoni C, et al. Cutaneous CD30+ cells in children with atopic dermatitis. *International archives of allergy and immunology* 2000; 121.
23. Bengtsson A, Holm L, Back O, Fransson J, Scheynius A. Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). *Clinical and experimental immunology* 1997; 109.
24. Caproni M, Salvatore E, Cardinali C, Brazzini B, Fabbri P. Soluble CD30 and cyclosporine in severe atopic dermatitis. *International archives of allergy and immunology* 2000; 121.
25. Holm L, Bengtsson A, van Hage-Hamsten M, Ohman S, Scheynius A. Effectiveness of occlusive bedding in the treatment of atopic dermatitis--a placebo-controlled trial of 12 months' duration. *Allergy* 2001; 56.

26. Folster-Holst R, Henseler T, Wehde J, Lemke H, Weichenthal M, Christophers E, et al. Soluble CD30 plasma concentrations correlate with disease activity in patients with atopic dermatitis. *Acta Dermato-Venereologica* 2002; 82.
27. Frezzolini A, Paradisi M, Zaffiro A, Provini A, Cadoni S, Ruffelli M, et al. Circulating interleukin 16 (IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): a novel serological marker of disease activity. *Allergy* 2002; 57.
28. Heshmat NM, El-Hadidi ES. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2006; 17.
29. Noh G, Lozano F. Intravenous immune globulin effects on serum-soluble CD5 levels in atopic dermatitis. *Clinical and Experimental Allergy*, 2001:1932-8.
30. Hon KL, Leung TF, Wong Y, Lam WK, Guan DQ, Ma KC, et al. A pentaherbs capsule as a treatment option for atopic dermatitis in children: an open-labeled case series. *The American Journal of Chinese Medicine* 2004; 32.
31. Song TW, Sohn MH, Kim ES, Kim KW, Kim KE. Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2006; 36.
32. Machura E, Rusek-Zychma M, Jachimowicz M, Wrzask M, Mazur B, Kasperska-Zajac A. Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria. *Pediatric Allergy and Immunology* 2011.
33. Paganelli R, Fanales-Belasio E, Carmini D, Scala E, Meglio P, Businco L, et al. Serum eosinophil cationic protein in patients with atopic dermatitis. *International archives of allergy and applied immunology* 1991; 96.
34. Czech W, Krutmann J, Schopf E, Kapp A. Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. *The British journal of dermatology* 1992; 126.
35. Furue M, Sugiyama H, Tsukamoto K, Ohtake N, Tamaki K. Serum soluble IL-2 receptor (sIL-2R) and eosinophil cationic protein (ECP) levels in atopic dermatitis. *Journal of dermatological science* 1994; 7.
36. Kojima T, Ono A, Aoki T, Kameda-Hayashi N, Kobayashi Y. Circulating ICAM-1 levels in children with atopic dermatitis. *Annals of Allergy* 1994; 73.

37. Kowalzik L, Kleinheinz A, Weichenthal M, Neuber K, Kohler I, Grosch J, et al. Low dose versus medium dose UV-A1 treatment in severe atopic eczema. *Acta Dermato-Venereologica* 1995; 75.
38. Musial J, Milewski M, Undas A, Kopinski P, Duplaga M, Szczeklik A. Interferon-gamma in the treatment of atopic dermatitis: influence on T-cell activation. *Allergy* 1995; 50.
39. Park JH, Choi YL, Namkung JH, Kim WS, Lee JH, Park HJ, et al. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. *The British journal of dermatology* 2006; 155.
40. Murat-Susic S, Lipozencic J, Zizic V, Husar K, Marinovic B. Serum eosinophil cationic protein in children with atopic dermatitis. *International journal of dermatology* 2006; 45.
41. Gambichler T, Othlinghaus N, Tomi NS, Holland-Letz T, Boms S, Skrygan M, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. *The British journal of dermatology* 2009; 160.
42. Oh J, Jee S, Lee H. The efficacy of intravenous immunoglobulin injection for moderate to severe atopic dermatitis in childhood. *Journal of Allergy and Clinical Immunology* 2010; 125:AB90.
43. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. *Allergy* 2005; 60.
44. Yamashita N, Kaneko S, Kouro O, Furue M, Yamamoto S, Sakane T. Soluble E-selectin as a marker of disease activity in atopic dermatitis. *The Journal of allergy and clinical immunology* 1997; 99.
45. Keller S, Le HY, Rodiger C, Hipler UC, Kertscher R, Malarski A, et al. Supplementation of a dairy drink enriched with milk phospholipids in patients with atopic dermatitis - A double-blind, placebo-controlled, randomized, cross-over study. *Clinical Nutrition* 2014.
46. Johnson EE, Irons JS, Patterson R, Roberts M. Serum IgE concentration in atopic dermatitis. Relationship to severity of disease and presence of atopic respiratory disease. *J Allergy Clin Immunol* 1974; 54:94-9.
47. Hoffman DR, Yamamoto FY, Geller B, Haddad Z. Specific IgE antibodies in atopic eczema. *Journal of Allergy and Clinical Immunology* 1975; 55:256-67.
48. Church JA, Kleban DG, Bellanti JA. Serum immunoglobulin E concentrations and radioallergosorbent tests in children with atopic dermatitis. *Pediatr Res* 1976; 10:97-9.
49. Abbott JK, Howell M, Lesley L, Inderlied C, Church JA, Leung DY, et al. Mechanisms of staphylococcus aureus clearance after wetwrap treatment in severe atopic dermatitis patients. *Journal of Allergy and Clinical Immunology* 2009; 123:S36.

50. Boguniewicz M, Jaffe HS, Izu A, Sullivan MJ, York D, Geha RS, et al. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. *Am J Med* 1990; 88:365-70.
51. Matsumoto T, Miike T, Yamaguchi K, Murakami M, Kawabe T, Yodoi J. Serum levels of soluble IL-2 receptor, IL-4 and IgE-binding factors in childhood allergic diseases. *Clinical and experimental immunology* 1991; 85.
52. Sanda T, Yasue T, Oohashi M, Yasue A. Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis. *Journal of Allergy and Clinical Immunology*, 1992:653-7.
53. Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, et al. Recombinant interferon gamma therapy for atopic dermatitis. *Journal of the American Academy of Dermatology*, 1993:189-97.
54. Back O, Scheynius A, Johansson SG. Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. *Arch Dermatol Res* 1995; 287:448-51.
55. Gebhardt M, Wenzel HC, Hipler UC, Herrmann D, Wollina U. Monitoring of serologic immune parameters in inflammatory skin diseases. *Allergy* 1997; 52.
56. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. *Arch Dermatol* 1998; 134:799-804.
57. Henz BM, Jablonska S, Kerkhof PC, Stingl G, Blaszczyk M, Vandervalk PG, et al. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. *British Journal of Dermatology*, 1999:685-8.
58. Nomura I, Tanaka K, Tomita H, Katsunuma T, Ohya Y, Ikeda N, et al. Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis. *J Allergy Clin Immunol* 1999; 104:441-6.
59. Kato M, Nagata Y, Tanabe A, Ikemoto A, Watanabe S, Kobayashi T, et al. Supplementary treatment of atopic dermatitis patients by choosing foods to lower the N - 6/N - 3 ratio of fatty acids. *Journal of Health Science* 2000; 46:241-50.
60. Patrizi A, Guerrini V, Ricci G, Neri I, Specchia F, Masi M. The natural history of sensitizations to food and aeroallergens in atopic dermatitis: a 4-year follow-Up. *Pediatr Dermatol* 2000; 17:261-5.

61. Yoshizawa Y, Matsui H, Izaki S, Kitamura K, Maibach HI. Topical dinitrochlorobenzene therapy in the treatment of refractory atopic dermatitis: systemic immunotherapy. *J Am Acad Dermatol* 2000; 42:258-62.
62. Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. *Allergy*, 2001:512-7.
63. Tanaka T, Kouda K, Kotani M, Takeuchi A, Tabei T, Masamoto Y, et al. Vegetarian diet ameliorates symptoms of atopic dermatitis through reduction of the number of peripheral eosinophils and of PGE2 synthesis by monocytes. *J Physiol Anthropol Appl Human Sci* 2001; 20:353-61.
64. Yoshizawa Y, Nomaguchi H, Izaki S, Kitamura K. Serum cytokine levels in atopic dermatitis. *Clinical and experimental dermatology* 2002; 27.
65. Gool CJ, Thijs C, Henquet CJ, Houwelingen AC, Dagnelie PC, Schrandt J, et al. Gamma-linolenic acid supplementation for prophylaxis of atopic dermatitis--a randomized controlled trial in infants at high familial risk. *American journal of clinical nutrition*, 2003:943-51.
66. Kaneko S, Furutani K, Koro O, Yamamoto S. Transient shift toward T helper 1 cytokine production by peripheral blood mononuclear cells following successful treatment of patients with atopic dermatitis. *Allergology International* 2003; 52.
67. Laske N, Niggemann B. Does the severity of atopic dermatitis correlate with serum IgE levels? *Pediatr Allergy Immunol* 2004; 15:86-8.
68. Bordignon V, Sinagra JL, Trento E, Pietravalle M, Capitanio B, Cordiali Fei P. Antigen specific cytokine response in pediatric patients with atopic dermatitis. *Pediatr Allergy Immunol* 2005; 16:113-20.
69. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. *J Am Acad Dermatol* 2005; 53:S206-13.
70. Aral M, Arican O, Gul M, Sasmaz S, Kocturk SA, Kastal U, et al. The relationship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease severity in children with atopic dermatitis. *Mediators of inflammation* 2006; 2006.
71. Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2007; 37.

72. Cadario G, Galluccio AG, Pezza M, Appino A, Milani M, Pecora S, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. *Curr Med Res Opin* 2007; 23:2503-6.
73. Grüber C, Wendt M, Sulser C, Lau S, Kulig M, Wahn U, et al. Randomized, placebo-controlled trial of *Lactobacillus rhamnosus* GG as treatment of atopic dermatitis in infancy. *Allergy*, 2007;1270-6.
74. Fathi G, Saber K, Shaaban F, Fakhry D. Increased urinary leukotriene E4 and its correlation to severity and laboratory markers of atopic dermatitis in children. *Journal of Medical Sciences* 2007; 7.
75. Katoh N, Hirano S, Kishimoto S. Prognostic factor of adult patients with atopic dermatitis. *J Dermatol* 2008; 35:477-83.
76. Park do S, Youn YH. Clinical significance of serum interleukin-18 concentration in the patients with atopic dermatitis. *The Korean journal of laboratory medicine* 2007; 27.
77. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. *J Allergy Clin Immunol* 2008; 121:122-8.
78. Gerdes S, Kurrat W, Mrowietz U. Serum mast cell tryptase is not a useful marker for disease severity in psoriasis or atopic dermatitis. *Br J Dermatol* 2009; 160:736-40.
79. Kwon YS, Oh SH, Wu WH, Bae BG, Lee HJ, Lee MG, et al. CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy. *Experimental dermatology* 2010; 19.
80. van Velsen SG, Haeck IM, Bruijnzeel-Koomen CA, de Bruin-Weller MS. First experience with enteric-coated mycophenolate sodium (Myfortic) in severe recalcitrant adult atopic dermatitis: an open label study. *The British journal of dermatology* 2009; 160.
81. Kayserova J, Capkova S, Skalicka A, Vernerova E, Polouckova A, Malinova V, et al. Serum immunoglobulin free light chains in severe forms of atopic dermatitis. *Scand J Immunol* 2010; 71:312-6.
82. Mandelin JM, Remitz A, Virtanen HM, Malmberg LP, Haahtela T, Reitamo S. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. *J Dermatolog Treat* 2010; 21:167-70.
83. Morishima Y, Kawashima H, Takekuma K, Hoshika A. Changes in serum lactate dehydrogenase activity in children with atopic dermatitis. *Pediatr Int* 2010; 52:171-4.

84. Van Der Aa L, Heymans H, Van Aalderen W, Sillevs Smitt H, Knol J, Goossens D, et al. Effect of a new synbiotic mixture on atopic dermatitis in infants: A randomised controlled trial. *Allergy: European Journal of Allergy and Clinical Immunology* 2009; 64:278.
85. Akan A, Erkocoglu M, Kaya A, Azkur D, Ozcan C, Toyran M, et al. Single center experience: Clinical features of children with atopic dermatitis. *Clinical and Translational Allergy* 2011; 1.
86. Alendar F. Correlation between clinical symptoms of atopic dermatitis in children and serum IgE level. *Med Arh* 2011; 65:168-9.
87. Jin YY, Cao RM, Chen J, Kaku Y, Wu J, Cheng Y, et al. Partially hydrolyzed cow's milk formula has a therapeutic effect on the infants with mild to moderate atopic dermatitis: a randomized, double-blind study. *Pediatric Allergy and Immunology*, 2011:688-94.
88. Nagy G, Gaspar K, Irinyi B, Gal M, Tumpek J, Gyimesi E, et al. Association between serum IL-16 levels and the degree of sensitization in patients with atopic dermatitis. *International archives of allergy and immunology* 2011; 156.
89. Panahi Y, Davoudi SM, Madanchi N, Abolhasani E. Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis. *Clin Exp Med* 2012; 12.
90. Vakirlis E, Lazaridou E, Tzellos TG, Gerou S, Chatzidimitriou D, Ioannides D. Investigation of cytokine levels and their association with SCORAD index in adults with acute atopic dermatitis. *Journal of the European Academy of Dermatology and Venereology : JEADV* 2011; 25.
91. Addor FA, Takaoka R, Rivitti EA, Aoki V. Atopic dermatitis: correlation between non-damaged skin barrier function and disease activity. *Int J Dermatol* 2012; 51:672-6.
92. Hon KL, Lo W, Cheng WK, Leung TF, Chow CM, Lau CB, et al. Prospective self-controlled trial of the efficacy and tolerability of a herbal syrup for young children with eczema. *J Dermatolog Treat* 2012; 23:116-21.
93. Kou K, Aihara M, Matsunaga T, Chen H, Taguri M, Morita S, et al. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. *Arch Dermatol Res* 2012; 304.
94. Lee JH, Noh G. Polydesensitisation with reducing elevated serum total IgE by IFN-gamma therapy in atopic dermatitis: IFN-gamma and polydesensitisation (PDS). *Cytokine* 2013; 64:395-403.
95. Lee SA, Hong S, Kim HJ, Lee SH, Yum HY. Correlation between serum vitamin D level and the severity of atopic dermatitis associated with food sensitization. *Allergy, Asthma and Immunology Research* 2013; 5:207-10.

96. Li S, Kuchta K, Tamaru N, Lin Y, Iwasaki S, Wang R, et al. Efficacy of a novel herbal multicomponent traditional Chinese medicine therapy approach in patients with atopic dermatitis. *Forsch Komplementmed* 2013; 20:189-96.
97. Mizawa M, Yamaguchi M, Ueda C, Makino T, Shimizu T. Stress evaluation in adult patients with atopic dermatitis using salivary cortisol. *Biomed Res Int* 2013; 2013:138027.
98. Orfali RL, Sato MN, Dos Santos VG, Titz TO, Duarte AS, Takaoka R, et al. Atopic dermatitis in adults: Augmented circulating IgG4 and IgE antibodies against *Staphylococcus aureus* enterotoxin B. *Journal of Investigative Dermatology* 2013; 133:S44.
99. Suarez-Farinas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. *J Allergy Clin Immunol* 2013; 132:361-70.
100. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *New England Journal of Medicine*, 2014:130-9.
101. Brodska P, Panzner P, Pizinger K, Schmid-Grendelmeier P. IgE-mediated sensitization to malassezia in atopic dermatitis: More common in male patients and in head and neck type. *Dermatitis* 2014; 25:120-6.
102. Kataoka Y. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. *Journal of Dermatology* 2014; 41:221-9.
103. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. *J Allergy Clin Immunol* 2014; 133:1626-34.
104. Kou K, Okawa T, Yamaguchi Y, Ono J, Inoue Y, Kohno M, et al. Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis. *British Journal of Dermatology* 2014; 171:283-91.
105. Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P. *The British journal of dermatology* 2007; 157.
106. Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of beta-thromboglobulin and platelet factor 4. *Allergol Int* 2008; 57:391-6.

107. Katoh N, Hirano S, Suehiro M, Ikenaga K, Yamashita T, Sugawara N, et al. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. *Clinical and experimental immunology* 2000; 121.
108. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. *International Archives of Allergy and Immunology*, 2013:89-93.
109. Yang HJ, Min TK, Lee HW, Pyun BY. Efficacy of probiotic therapy on atopic dermatitis in children: A randomized, double-blind, placebo-controlled trial. *Allergy, asthma & immunology research*, 2014:208-15.
110. Latief, El-Bendary A, Abu-Raya A, Hodeib A. Nerve growth factor, neuropeptides and cutaneous nerves in atopic dermatitis. *Indian journal of dermatology* 2010; 55.
111. Bae BG, Oh SH, Park CO, Noh S, Noh JY, Kim KR, et al. Progressive muscle relaxation therapy for atopic dermatitis: objective assessment of efficacy. *Acta Derm Venereol* 2012; 92.
112. Angelova-Fischer I, Hipler UC, Bauer A, Fluhr JW, Tsankov N, Fischer TW, et al. Significance of interleukin-16, macrophage-derived chemokine, eosinophil cationic protein and soluble E-selectin in reflecting disease activity of atopic dermatitis - From laboratory parameters to clinical scores. *British Journal of Dermatology* 2006; 154.
113. Masuda K, Katoh N, Okuda F, Kishimoto S. Increased levels of serum interleukin-16 in adult type atopic dermatitis. *Acta Dermato-Venereologica* 2003; 83.
114. Morioka J, Tomita M, Yoshizawa Y, Inamura H, Kurosawa M. Concentrations of eosinophil-derived neurotoxin in the blood and urine of patients with allergic diseases. *Allergology International* 2004; 53:359-67.
115. Kim E, Lee JE, Namkung JH, Park JH, Kim S, Shin ES, et al. Association of the single-nucleotide polymorphism and haplotype of the interleukin 18 gene with atopic dermatitis in Koreans. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2007; 37.
116. Hon KL, Leung TF, Ma KC, Wong CK, Wan H, Lam CW. Serum concentration of IL-18 correlates with disease extent in young children with atopic dermatitis. *Pediatric dermatology* 2004; 21.
117. Trzeciak M, Glen J, Bandurski T, Sokolowska-Wojdylo M, Wilkowska A, Roszkiewicz J. Relationship between serum levels of interleukin-18, IgE and disease severity in patients with atopic dermatitis. *Clinical and experimental dermatology* 2011; 36.

118. Fujisawa T, Fujisawa R, Kato Y, Nakayama T, Morita A, Katsumata H, et al. Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. *The Journal of allergy and clinical immunology* 2002; 110.
119. Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. *Clinical and Experimental Allergy*, 2000:1604-10.
120. Wolkerstorfer A, Laan MP, Savelkoul HF, Neijens HJ, Mulder PG, Oudesluys-Murphy AM, et al. Soluble E-selectin, other markers of inflammation and disease severity in children with atopic dermatitis. *The British journal of dermatology* 1998; 138.
121. Wuthrich B, Kagi MK, Joller-Jemelka H. Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis. *Archives of Dermatological Research* 1992; 284.
122. Kagi MK, Joller-Jemelka H, Wuthrich B. Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. *Dermatology (Basel, Switzerland)* 1992; 185.
123. Halmerbauer G, Frischer T, Koller DY. Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. *Allergy* 1997; 52.
124. von Kobyletzki G, Pieck C, Hoxtermann S, Freitag M, Altmeyer P. Circulating activation markers of severe atopic dermatitis following ultraviolet A1 cold light phototherapy: eosinophil cationic protein, soluble interleukin-2 receptor and soluble interleukin-4 receptor. *The British journal of dermatology* 1999; 140.
125. Huang JL, Lee WY, Chen LC, Kuo ML, Hsieh KH. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. *Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology* 2000; 84.
126. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. *Clinical and experimental immunology* 2002; 127.
127. Colver GB, Symons JA, Duff GW. Soluble interleukin 2 receptor in atopic eczema. *BMJ* 1989; 298:1426-8.

128. Yoshikawa K, Ishii M, Chanoki M, Okano M, Sugai T, Abe Y, et al. Relationship of the severity of atopic dermatitis with nonspecific IgE, serum LDH, eosinophil counts in patients given the anti-allergic agent oxatomide. *Skin Research* 2000; 42:276-84.
129. Raap U, Wichmann K, Bruder M, Stander S, Wedi B, Kapp A, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. *The Journal of allergy and clinical immunology* 2008; 122.
130. Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. *Journal of the European Academy of Dermatology and Venereology : JEADV* 2011; 25.
131. Otsuka A, Honda T, Doi H, Miyachi Y, Kabashima K. An H1-histamine receptor antagonist decreases serum interleukin-31 levels in patients with atopic dermatitis. *The British journal of dermatology* 2011; 164.
132. Lee CH, Hong CH, Yu WT, Chuang HY, Huang SK, Chen GS, et al. Mechanistic correlations between two itch biomarkers, cytokine interleukin-31 and neuropeptide beta-endorphin, via STAT3/calcium axis in atopic dermatitis. *Br J Dermatol* 2012; 167.
133. Kyoya M, Kawakami T, Soma Y. Serum thymus and activation-regulated chemokine (TARC) and interleukin-31 levels as biomarkers for monitoring in adult atopic dermatitis. *Journal of Dermatological Science* 2014; 75:204-7.
134. Tamagawa-Mineoka R, Okuzawa Y, Masuda K, Katoh N. Increased serum levels of interleukin 33 in patients with atopic dermatitis. *J Am Acad Dermatol* 2014; 70:882-8.
135. Byun HJ, Lee HI, Kim B, Kim MN, Hong H, Choi Y, et al. Full-spectrum light phototherapy for atopic dermatitis. 2011.
136. Nada HA, Gomaa NIM, Elakhras A, Wasfy R, Baker RA. Skin colonization by superantigen-producing *Staphylococcus aureus* in Egyptian patients with atopic dermatitis and its relation to disease severity and serum interleukin-4 level. *International Journal of Infectious Diseases* 2011.
137. Kwon HB, Ahn BJ, Choi Y, Jin SY, Cheong KA, Lee J, et al. Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: a pilot study. *Journal of Dermatology*, 2013:207-10.
138. Nutan FN, Kanwar AJ, Parsad D. The effect of topically applied corticosteroids on interleukin 1beta levels in patients with atopic dermatitis. *J Eur Acad Dermatol Venereol* 2012; 26:1020-2.
139. Park CW, Lee BH, Han HJ, Lee CH, Ahn HK. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. *Br J Dermatol* 2005; 152:1173-81.

140. Kimura T, Sugaya M, Suga H, Morimura S, Miyamoto A, Kai H, et al. Variations in serum TARC and I-TAC levels reflect minor changes in disease activity and pruritus in atopic dermatitis. *Acta Dermato-Venereologica* 2014; 94:331-2.
141. Ciprandi G, De Amici M, Giunta V, Marseglia A, Marseglia G. Serum interleukin-9 levels are associated with clinical severity in children with atopic dermatitis. *Pediatr Dermatol* 2013; 30:222-5.
142. Ma L, Xue HB, Guan XH, Shu CM, Zhang JH, Yu J. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. *Clin Exp Immunol* 2014; 175:25-31.
143. Devillers AC, van Toorenenbergen AW, Klein Heerenbrink GJ, Muldert PG, Oranje AP. Elevated levels of plasma matrix metalloproteinase-9 in patients with atopic dermatitis: a pilot study. *Clin Exp Dermatol* 2007; 32:311-3.
144. Fukuda H, Suzuki T, Saotome A, Sode E, Mukai H. Efficacy of inpatient treatment for atopic dermatitis evaluated by changes in serum cortisol levels. *J Dermatol* 2013; 40:43-7.
145. Leung TF, Ching KW, Kong AP, Wong GW, Chan JC, Hon KL. Circulating LL-37 is a biomarker for eczema severity in children. *J Eur Acad Dermatol Venereol* 2012; 26:518-22.
146. Morita H, Kitano Y, Kawasaki N. Elevation of serum-soluble E-selectin in atopic dermatitis. *Journal of dermatological science* 1995; 10.
147. Ikai K, Nakajima N, Ozaki M, Furukawa I, Aoshima T, Mitani T, et al. Serum level of major basic protein indicates disease activity in atopic dermatitis. *Journal of the European Academy of Dermatology and Venereology* 1997; 9:54-6.
148. Yoshijima S, Kojima T, Sasai M, Hattori K, Taniuchi S, Kobayashi Y. Plasma thrombomodulin levels in children with atopic dermatitis. *Acta Paediatr* 2001; 90:130-2.
149. Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N. Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2008; 19.
150. Leung TF, Ma KC, Hon KL, Lam CW, Wan H, Li CY, et al. Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2003; 14.

151. Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. *Journal of dermatological science* 2004; 34.
152. Mostafa GA, Tomoum HY, Salem SA, Abd El-Aziz MM, Abou El-Maged DI, El-Sayed El-Far I. Serum concentrations of CCR4 ligands in relation to clinical severity of atopic dermatitis in Egyptian children. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2008; 19.
153. Koczy-Baron E, Jochem J, Kasperska-Zajac A. Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activation. *Inflamm Res* 2012; 61:1405-9.
154. Matsushita T, Fujimoto M, Echigo T, Matsushita Y, Shimada Y, Hasegawa M, et al. Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis. *Exp Dermatol* 2008; 17:197-202.
155. Ibrahim ZA, Ghaly NR, El-Tatawy RA, Khalil SM, El-Batch MM. A proliferation-inducing ligand in atopic dermatitis and vitiligo. *International Journal of Dermatology* 2014; 53:1073-9.
156. Nakao M, Sugaya M, Suga H, Kawaguchi M, Morimura S, Kai H, et al. Serum autotaxin levels correlate with pruritus in patients with atopic dermatitis. *J Invest Dermatol* 2014; 134:1745-7.
157. Raap U, Werfel T, Goltz C, Deneka N, Langer K, Bruder M, et al. Circulating levels of brain-derived neurotrophic factor correlate with disease severity in the intrinsic type of atopic dermatitis. *Allergy* 2006; 61.
158. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. *The British journal of dermatology* 2002; 147.
159. Schulte-Herbruggen O, Folster-Holst R, von Elstermann M, Augustin M, Hellweg R. Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis. *International archives of allergy and immunology* 2007; 144.
160. Kim HO, Lee CH, Ahn HK, Park CW. Effects of tacrolimus ointment on the expression of substance P, nerve growth factor, and neurotrophin-3 in atopic dermatitis. *International journal of dermatology* 2009; 48.
161. Papoiu ADP, Wang H, Nattkemper L, Tey HL, Ishiuiji Y, Chan YH, et al. A study of serum concentrations and dermal levels of NGF in atopic dermatitis and healthy subjects. *Neuropeptides* 2011.

162. Taniuchi S, Chihara J, Kojima T, Yamamoto A, Sasai M, Kobayashi Y. Serum eosinophil derived neurotoxin may reflect more strongly disease severity in childhood atopic dermatitis than eosinophil cationic protein. *Journal of dermatological science* 2001; 26.
163. Namura K, Hasegawa G, Egawa M, Matsumoto T, Kobayashi R, Yano T, et al. Relationship of serum brain-derived neurotrophic factor level with other markers of disease severity in patients with atopic dermatitis. *Clinical immunology (Orlando, Fla.)* 2007; 122.
164. Sumegi A, Szegedi A, Gal M, Hunyadi J, Szegedi G, Antal-Szalmas P. Analysis of components of the CD14/TLR system on leukocytes of patients with atopic dermatitis. *International archives of allergy and immunology* 2007; 143.
165. Ott H, Wilke J, Baron JM, Hoger PH, Folster-Holst R. Soluble immune receptor serum levels are associated with age, but not with clinical phenotype or disease severity in childhood atopic dermatitis. *Journal of the European Academy of Dermatology and Venereology : JEADV* 2010; 24.
166. Miyagaki T, Sugaya M, Suga H, Morimura S, Kamata M, Ohmatsu H, et al. Serum soluble CD26 levels: diagnostic efficiency for atopic dermatitis, cutaneous T-cell lymphoma and psoriasis in combination with serum thymus and activation-regulated chemokine levels. *Journal of the European Academy of Dermatology and Venereology* 2011.
167. Frezzolini A, Paradisi M, Ruffelli M, Cadoni S, De Pita O. Soluble CD30 in pediatric patients with atopic dermatitis. *Allergy* 1997; 52.
168. Caproni M, Bianchi B, D'Elis MM, De Carli M, Amedei A, Fabbri P. In vivo relevance of CD30 in atopic dermatitis. *Allergy* 1997; 52.
169. Di Lorenzo G, Gangemi S, Merendino RA, Minciullo PL, Cannavo SP, Martinelli N, et al. Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index. *Mediators of inflammation* 2003; 12.
170. Mitsuishi K, Nakamura T, Sakata Y, Yuyama N, Arima K, Sugita Y, et al. The squamous cell carcinoma antigens as relevant biomarkers of atopic dermatitis. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2005; 35.
171. Lin YT, Shau WY, Wang LF, Yang YH, Hwang YW, Tsai MJ, et al. Comparison of serum specific IgE antibodies to staphylococcal enterotoxins between atopic children with and without atopic dermatitis. *Allergy* 2000; 55:641-6.

172. Fukuie T, Matsumoto K, Narita M, Nomura I, Tokura Y, Ohya Y. Does proactive management of atopic dermatitis affect sensitization or tolerance? A randomized controlled study. *Allergy: European Journal of Allergy and Clinical Immunology* 2013; 68:37.
173. Kanbe T, Soma Y, Kawa Y, Kashima M, Mizoguchi M. Serum levels of soluble stem cell factor and soluble KIT are elevated in patients with atopic dermatitis and correlate with the disease severity. *The British journal of dermatology* 2001; 144.
174. Hosokawa C, Takeuchi S, Furue M. Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride. *The Journal of dermatology* 2009; 36.
175. Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. *The Journal of allergy and clinical immunology* 2004; 113.
176. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. *The Journal of allergy and clinical immunology* 2001; 107.
177. Haeck IM, Timmer-de Mik L, Lentjes EG, Buskens E, Hijnen DJ, Guikers C, et al. Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused. *The British journal of dermatology* 2007; 156.
178. Fujisawa T, Nagao M, Hiraguchi Y, Katsumata H, Nishimori H, Iguchi K, et al. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2009; 20.
179. Haeck IM, Knol MJ, Ten BO, Van Velsen SGA, De Bruin-Weller MS, Bruijnzeel-Koomen CAFM. Enteric-Coated Mycophenolate Sodium versus Cyclosporine A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial. *Allergo Journal* 2010; 19:340-1.
180. Haeck IM, Ten Berge O, Van Velsen SGA, De Bruin-Weller MS, Bruijnzeel-Koomen CAFM, Knol MJ. Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis. *Allergo Journal* 2010; 19:311.

181. van Velsen SG, Knol MJ, Haeck IM, Bruijnzeel-Koomen CA, Pasmans SG. The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity. *Pediatric dermatology* 2010; 27.
182. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. *Journal of the American Academy of Dermatology* 2011; 64.
183. Schram ME, Roekevisch E, Leeftang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. *The Journal of allergy and clinical immunology* 2011; 128.
184. Torii S, Torii A, Itoh K, Urisu A, Terada A, Fujisawa T, et al. Effects of oral administration of *Lactobacillus acidophilus* L-92 on the symptoms and serum markers of atopic dermatitis in children. *International archives of allergy and immunology* 2011; 154.
185. Landheer J, de Bruin-Weller M, Boonacker C, Hijnen D, Bruijnzeel-Koomen C, Rockmann H. Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity. *Journal of the American Academy of Dermatology* 2014.
186. Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Asano N, Mitsui H, et al. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. *The Journal of allergy and clinical immunology* 2003; 111.
187. Hon KL, Leung TF, Ma KC, Li AM, Wong Y, Fok TF. Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children. *Clinical and experimental dermatology* 2004; 29.
188. Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schopf E. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. *Journal of the American Academy of Dermatology* 1992; 26.
189. Sugai T, Sakiyama Y, Matumoto S. Eosinophil cationic protein in peripheral blood of pediatric patients with allergic diseases. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 1992; 22.
190. Kato K. Increased sensitivity of eosinophils for eosinophilopoietic cytokines in atopic dermatitis. *The Kurume medical journal* 1995; 42.
191. Nakama T. Relationships between eosinophil-associated parameters and disease severity in atopic dermatitis. *The Kurume medical journal* 1995; 42.

192. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. *The Journal of allergy and clinical immunology* 1997; 99.
193. Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Sonnichsen N, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. *Journal of the American Academy of Dermatology* 1998; 38.
194. Simon D, Weigl L, Disch R. Influence of high-altitude climate therapy on atopic eczema. *Allergologie* 1999; 22.
195. Amon U, Memmel U, Stoll R, Amon S. Comparison of severity scoring of atopic dermatitis values and serum levels of eosinophil cationic protein and mast cell tryptase for routine evaluation of atopic dermatitis. *Acta Dermato-Venereologica* 2000; 80.
196. Gebhart E, Verdorfer I, Saul W, Trautmann U, Brecevic L. Delimiting the use of comparative genomic hybridization in human myeloid neoplastic disorders. *Int J Oncol* 2000; 16:1099-105.
197. Pucci N, Lombardi E, Novembre E, Farina S, Bernardini R, Rossi E, et al. Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. *The Journal of allergy and clinical immunology* 2000; 105.
198. Worm M, Ehlers I, Sterry W, Zuberbier T. Clinical relevance of food additives in adult patients with atopic dermatitis. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2000; 30.
199. Breuer K, Kapp A, Werfel T. Urine eosinophil protein X (EPX) is an in vitro parameter of inflammation in atopic dermatitis of the adult age. *Allergy* 2001; 56.
200. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. *European journal of dermatology : EJD* 2001; 11.
201. Capoluongo E, Giglio AA, Lavieri MM, Lesnoni-La Parola I, Ferraro C, Cristaudo A, et al. Genotypic and phenotypic characterization of *Staphylococcus aureus* strains isolated in subjects with atopic dermatitis. Higher prevalence of exfoliative B toxin production in lesional strains and correlation between the markers of disease intensity and colonization density. *Journal of dermatological science* 2001; 26.
202. Gutgesell C, Heise S, Seubert A, Stichtenoth DO, Frolich JC, Neumann C. Comparison of different activity parameters in atopic dermatitis: correlation with clinical scores. *The British journal of dermatology* 2002; 147.

203. Petermann F, Gulyas AF, Niebank K, Warschburger P. Effects of Allergen Avoidance at High Altitude on Children with Asthma or Atopic Dermatitis. *Pediatric Asthma, Allergy and Immunology* 2004; 17.
204. Wu KG, Li TH, Peng HJ. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. *Br J Dermatol* 2012; 166.
205. Kim SW, Sung SM. Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in pediatrics. *Allergy: European Journal of Allergy and Clinical Immunology* 2013; 68:439.
206. Sumimoto S, Kawai M, Kasajima Y, Hamamoto T. Increased plasma tumour necrosis factor-alpha concentration in atopic dermatitis. *Arch Dis Child* 1992; 67:277-9.
207. Lee EB, Kim KW, Hong JY, Jee HM, Sohn MH, Kim KE. Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. *Pediatr Allergy Immunol* 2010; 21:e457-60.
208. Madej A, Reich A, Orda A, Szepietowski JC. Expression of vascular adhesion protein-1 in atopic eczema. *Int Arch Allergy Immunol* 2006; 139:114-21.
209. Wolkerstorfer A, Savelkoul HF, de Waard van der Spek FB, Neijens HJ, van Meurs T, Oranje AP. Soluble E-selectin and soluble ICAM-1 levels as markers of the activity of atopic dermatitis in children. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2003; 14.
210. Czech W, Schopf E, Kapp A. Soluble E-selectin in sera of patients with atopic dermatitis and psoriasis--correlation with disease activity. *The British journal of dermatology* 1996; 134.
211. Laan MP, Koning H, Baert MR, Oranje AP, Buurman WA, Savelkoul HF, et al. Levels of soluble intercellular adhesion molecule-1, soluble E-selectin, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptor p55 and p75 in atopic children. *Allergy* 1998; 53.
212. Kagi MK, Joller-Jemelka H, Wuthrich B. Soluble E-selectin correlates with disease activity in cyclosporin A-treated patients with atopic dermatitis. *Allergy* 1999; 54.
213. Chen T, Guo ZP, Cao N, Qin S, Li MM, Jia RZ. Increased serum levels of soluble vascular endothelial-cadherin in patients with systemic vasculitis. *Rheumatology International* 2014; 34:1139-43.
214. Umemoto N, Kakurai M, Okazaki H, Kiyosawa T, Demitsu T, Nakagawa H. Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis. *J Dermatol Sci* 2003; 31:161-4.

215. Peroni DG, Piacentini GL, Cametti E, Chinellato I, Boner AL. Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children. *Br J Dermatol* 2011; 164:1078-82.
216. Akan A, Azkur D, Ginis T, Toyran M, Kaya A, Vezir E, et al. Vitamin D level in children is correlated with severity of atopic dermatitis but only in patients with allergic sensitizations. *Pediatr Dermatol* 2013; 30:359-63.
217. Chiu YE, Havens PL, Siegel DH, Ali O, Wang T, Holland KE, et al. Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity. *J Am Acad Dermatol* 2013; 69:40-6.
218. El Taieb MA, Fayed HM, Aly SS, Ibrahim AK. Assessment of serum 25-hydroxyvitamin d levels in children with atopic dermatitis: correlation with SCORAD index. *Dermatitis* 2013; 24:296-301.
219. Samochocki Z, Bogaczewicz J, Jeziorowska R, Sysa-Jedrzejowska A, Glinska O, Karczmarewicz E, et al. Vitamin D effects in atopic dermatitis. *J Am Acad Dermatol* 2013; 69:238-44.
220. Rose RF, Williams C, Oliphant T, Browne F, Turner D, Goulden V. Serum 25-hydroxyvitamin D levels in patients with atopic eczema and the influence of narrowband ultraviolet B phototherapy. *Photodermatology Photoimmunology and Photomedicine* 2014.
221. Wang SS, Hon KL, Kong APS, Pong HNH, Wong GWK, Leung TF. Vitamin D deficiency is associated with diagnosis and severity of childhood atopic dermatitis. *Pediatric Allergy and Immunology* 2014; 25:30-5.
222. Kagami S, Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Sasaki K, et al. Increased serum CCL28 levels in patients with atopic dermatitis, psoriasis vulgaris and bullous pemphigoid. *The Journal of investigative dermatology* 2005; 124.
223. Ezzat MH, Sallam MA, Shaheen KY. Serum mucosa-associated epithelial chemokine (MEC/CCL28) in atopic dermatitis: a specific marker for severity. *International journal of dermatology* 2009; 48.